1/ You’ve heard of biotech, but what is this TechBio thing VCs keep talking about? Our first blog post breaks it down 👇
medium.com/cantos-venture
Pinned Tweet
Show this thread
Follow
Amee Kapadia
@ameekapadia
Joined September 2020
Amee Kapadia’s Tweets
We’re going to space 🚀
Quote Tweet
Atomos tows a $16M load of funding to create tugboats in space tcrn.ch/3WJJZi9 by @Haje
15
We don't usually lead Series A's in our portfolio (only once before) but when we do... techcrunch.com/2023/01/27/spa is headed to orbit! 🚀🛰️💨
2
7
26
Ask anyone who knows Harshita even a little and they’ll probably tell you she changed their life in some way.
She’s incredibly talented, genuine, and gives her all + more. A true steal for any team
Quote Tweet
Hey everyone!
I'm looking for the next step in my career and reaching out for some help as I transition into a new role.
Unfortunately, I'm on an H-1B visa so only have 60 days to transition to a new role 
Quick, relevant info that might be useful 
Unfortunately, I'm on an H-1B visa so only have 60 days to transition to a new role
Quick, relevant info that might be useful Show this thread
4
Major pivots in bio (and deep tech) aren’t always straightforward.
Waypoint Bio’s Xinchen Wang joins us on Decoding Bio to share five lessons he’s learned navigating a #techbio pivot
2
3
30
Show this thread
How can you not want to work with them? SO excited for Dimension in the bio community 🧬🔬
Quote Tweet
0/ ...Hello World. We're excited to launch DIMENSION today!
dimensioncap.com
Show this thread
1
13
this one might be my favorite so far
2
Show this thread
this week in bio is back!
-FDA approvals from 2022 💊
-how early exposure to food affects adult taste preference 🍫
-ChatGPT x medicine 🩺
-the correlation between viral infection and neurodegenerative disease 🧠
-IP & assisted reproductive tech 👶
2
6
32
Show this thread
Best bio podcast out there
Quote Tweet
New podcast just dropped!
In "The World in A Grain of Sand", we break down an S1 from a recent biotech IPO. In this episode, @KdT_Ventures Partners @CmanMD and @mackhealy take a deep dive into a biotech that owns a piece of 25% (!) of all blockbuster drugs - Royalty Pharma. 
Show this thread
1
Results are too evenly split rn. Last day to vote!
Quote Tweet
"Hugging Face for bio" is...
Show this poll
Know anyone who started their career as an engineer on an H-1B and transitioned to VC? Would love to talk to someone who was able to successfully chart a path from Engineering to VC on a visa.
22
9
85
"Hugging Face for bio" is...
- just Hugging Face34.7%
- a new company30.5%
- i'm just here for results34.7%
308 votesFinal results
13
4
10
who says you can't build a biotech in your garage
Quote Tweet
It's just a little too warm to put the centrifuge on the porch, so this was our solution today.
3
you can argue the subjectivity of the actual numbers, but the relationship holds.
full analysis in this fascinating paper that's been making the rounds. a must-read for anyone in drug discovery
3
2
11
Show this thread
increasing the predictive validity of a tool by 0.1 is equivalent to a 40x increase in # of candidates tested
1
4
35
Show this thread
AI in bio doesn't need more hype—at least not til we have some more concrete data. Surge brings up some interesting questions...
Quote Tweet
I usually let this stuff go, but this is too over the top
In splashy #JPM23 PR, @abscibio claim they can de novo design antibodies from scratch, but they actually design just the CDR3 (of 6 total) of existing Tx antibodies to their orig targets.
That's not de novo design
Show this thread
1
1
21
A super talented friend is looking for a new role in Product or Data Analytics.
Has 3+ years of experience working at an early stage startup and wants to contribute in a more collaborative role. Who’s hiring?
3
12
Happy JPM to all who celebrate ☔️🧬
1
8
99
Send us your best predictions for 2023 and we’ll include them in a future newsletter!
📧: decodingtechbio@gmail.com
2
Show this thread
1
2
5
Show this thread
we took a stab at making 5 predictions on what’s coming in bio:
1. Biz model innovation becomes necessary
2. Big tech backs up the truck in bio
3. Year of the microglia
4. Enzyme combos drive genomic editing toolbox
5. Longitudinal data drives R&D towards chronic indications
4
4
52
Show this thread
🔬 TOP SCIENCE BREAKTHROUGHS 2022 🧬
What did we miss? 🤔
14
87
327
Show this thread
Public market performance of AI-enabled drug developers (a subset of the #TechBio space)
How they've performed (and why they've struggled):
7
17
98
Show this thread
Today we released our first-ever public Map demonstration, which dives into our process for navigating complex biological relationships to uncover potential new treatments for patients.
Join Founding Fellow, Mason Victors for a step-by-step tutorial:
17
61
This week in bio:
-the rise & fall of peer review
-predictive toxicology
-hormonal contraceptives & the brain
-microglia in neurodegneration
-AlphaFold & CASP15 results
and more in
1
2
21
Show this thread
this week in bio:
-elements of scientific communication (and how to make it better)
-what happened with Galactica
-frame editors
-predicting cell fate with omics
and more:
13
I've been thinking on startup valuations respective to scale and wrote about it to end the week.
7
7
51
TIL measles can trigger "immune amnesia"—when your immune system forgets about every pathogen its ever encountered.
This is akin to wiping all vaxx history, memory of flus, viruses, bacteria, etc🤯
1
12
Hormone science feels severely under-researched and under-invested in.
What’s the best paper or company you’ve seen in endocrinology?
5
6
64
AI is the language decoding biology and it's not just for proteins
4
28
Show this thread
Exciting news! We're looking for the next generation of space innovators to join our team as summer interns (both engineering and non-engineering). Check out our job listing here:indeed.com/job/summer-202
1
5
15
This week in bio (it was a big one):
-generative diffusion models for proteins
-the plot thickens on Alzheimer’s with new lecanemab data
-why clinical trials are so expensive
-reasons progress in biology is slow (and ways to speed it up)
and more in
3
3
25
Show this thread
Thoughtful as always, Shelby with another great post on limitations in AIDD
Quote Tweet
AI in drug discovery is going through a 'recalibration phase' 
I talk about the current criticisms and why they're temporary 
shelbyann.substack.com/p/the-recalibr
I talk about the current criticisms and why they're temporary
shelbyann.substack.com/p/the-recalibrShow this thread
1
1
6
So what's replacing homework now that we have ChatGPT?
3
17
Small molecules FTW. I don’t understand why the US wants to reduce private investment into small molecules over large molecules. Why reward longer exclusivity to modalities that have proven harder to genericize? Going generic is the whole point of exclusivity in the 1st place. 🤦♂️
Quote Tweet
This is a really important paper. Every CEO of a small molecule biotech company should see this as a celebration of their work… and a too-late defense against the IRA’s 9y price setting.
More attention needed to “generalized cost-effectiveness analysis” @IAmBiotech twitter.com/PeterNeumann11…
1
6
41